Anti-Malarial, Anti-Fungal Drugs Show Promise in AML

Video

Several anti-malarial and anti-fungal drugs might be able to overcome a previously unexploited mechanism that allows some leukemia cells to escape programmed cell death.

According to preclinical experiments, several already approved anti-malarial and anti-fungal drugs might be able to overcome a previously unexploited mechanism that allows some leukemia cells to escape programmed cell death.

In this video, study author Alexandre Chigaev, PhD, a research associate professor at the University of New Mexico’s Center for Molecular Discovery, discusses the findings. Click here to read more.

Related Videos
Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.
Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.
Expert on myelofibrosis
Expert on myelofibrosis
Experts on myelofibrosis
Expert on myelofibrosis
Expert on myelofibrosis
Expert on myelofibrosis
Related Content
FDA Warns BCMA-, CD19-Directed Autologous CAR T-Cell Therapy May Lead to T-Cell Malignancies

FDA Warns BCMA-, CD19-Directed Autologous CAR T-Cell Therapy May Lead to T-Cell Malignancies

November 29th 2023
Article

Six BCMA-directed, CD19-directed autologous CAR T-cell therapies are under investigation for the potential risk of T-cell malignancies.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Impact of GVHD Prophylaxis on CMV Reactivation and Disease After HLA-matched Peripheral Blood Stem Cell Transplantation

Impact of GVHD Prophylaxis on CMV Reactivation and Disease After HLA-matched Peripheral Blood Stem Cell Transplantation

November 22nd 2023
Article

A recent study published in Nucleus highlighted the impact of graft-vs-host disease prophylaxis on cytomegalovirus reactivation.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

CB-012 is set to be investigated as part of the phase 1 AMpLify trial in patients with relapsed/refractory acute myeloid leukemia.

FDA Clears IND Application for Anti–CLL-1 CAR T-Cell Therapy for R/R AML

October 26th 2023
Article

CB-012 is set to be investigated as part of the phase 1 AMpLify trial in patients with relapsed/refractory acute myeloid leukemia.

Notch Signaling Drives Intestinal Graft-versus-host Disease in Mice and Nonhuman Primates

Notch Signaling Drives Intestinal Graft-versus-host Disease in Mice and Nonhuman Primates

October 25th 2023
Article

Notch signaling acute gastrointestinal graft-vs-host disease was determined in a study analyzing mice and nonhuman primates.